Every Form 4 that Damora Therapeutics, Inc. (DMRA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DMRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DMRA filings page.
Damora Therapeutics, Inc. reported that director Andrew Cheng received a grant of 30,350 stock options on 2026-08-12. The options have an exercise price of $31.00 per share, are exercisable for 30,350 Ordinary Shares, and expire on 2036-08-12. They vest in equal monthly installments through August 12, 2029, subject to his continued service, and this grant brings his directly held option position to 30,350 derivative securities.
Damora Therapeutics, Inc. General Counsel Winslow Garrett reported routine equity compensation activity involving restricted stock units (RSUs) and a small share sale tied to taxes. On July 3, 2026, 680 RSUs were settled into 680 shares of common stock at a stated price of $0.00 per share as part of their scheduled vesting from a January 3, 2024 award. On the same date, 640 RSUs from this award remained outstanding. On July 6, 2026, 245 shares of common stock were sold at $29.98 per share to cover tax obligations in connection with the RSU vesting under the company’s 2020 Equity Incentive Plan, which the filing describes as a mandated, non-discretionary sale. Following these transactions, Garrett holds 2,289 shares of Damora Therapeutics common stock directly.
Damora Therapeutics director and officer Jennifer Jarrett received new equity awards as compensation. On March 30, 2026, she was granted stock options to purchase 1,500,000 shares of common stock at an exercise price of $25.50 per share, expiring March 30, 2036. The options vest 25% on March 30, 2027 and then in equal monthly installments through March 30, 2030, subject to continued service. She also received 500,000 restricted stock units, each representing one share of common stock, vesting 25% on each anniversary of the grant date over four years, also conditioned on continued service. Following these awards, she directly holds 500,000 shares of common stock and 1,500,000 options.
Damora Therapeutics, Inc. reported that its General Counsel, Winslow Garrett, received a grant of stock options covering 250,000 shares of common stock. The options have an exercise price of $23.05 per share and expire on March 23, 2036.
According to the terms, the award will vest 25% on March 23, 2027 and then in equal monthly installments through March 23, 2030, conditioned on continued service. Following this grant, Garrett holds 250,000 stock options directly.
Damora Therapeutics, Inc. director Turtle Cameron received a grant of stock options covering 37,313 shares of common stock. The options carry an exercise price of $23.05 per share and expire on March 23, 2036.
The award vests in equal monthly installments through March 23, 2029, as long as Cameron continues to provide service to the company. Following this grant, Cameron holds stock options for 37,313 underlying shares directly, reflecting a compensation-related equity award rather than an open-market share purchase or sale.
Damora Therapeutics director Michael Landsittel received a stock option grant covering 37,313 shares of common stock. The option has an exercise price of $23.05 per share and expires on March 23, 2036. It vests in equal monthly installments through March 23, 2029, contingent on his continued service. Following this grant, he holds options for 37,313 shares directly.
Damora Therapeutics, Inc. reported a Form 4 showing a grant of stock options linked to Fairmount-managed investment vehicles. An option for 37,313 shares of common stock with a $23.05 exercise price was awarded and is held indirectly by Peter Harwin for one or more Fairmount funds.
The option vests in equal monthly installments through March 23, 2029, contingent on Harwin’s continued service to Damora. Under his arrangement with Fairmount, any net cash or stock from this option must be turned over to Fairmount for the benefit of the relevant Fairmount fund, and the parties disclaim beneficial ownership beyond their pecuniary interest.
Damora Therapeutics, Inc. reported that director Christopher W. Cain was granted a stock option covering 37,313 shares of common stock at an exercise price of $23.05 per share. The option expires on March 23, 2036 and vests in equal monthly installments through March 23, 2029, conditioned on his continued service.
According to the disclosure, Cain holds this option for one or more investment vehicles managed by Fairmount Funds Management LLC, is required to turn over any net cash or stock from the option to Fairmount, and therefore disclaims beneficial ownership of both the option and the underlying shares. Fairmount also disclaims beneficial ownership except to the extent of its pecuniary interest.
Damora Therapeutics director Bruno Julianne received a stock option grant covering 37,313 shares of common stock. The option has an exercise price of $23.05 per share, carries no upfront cost, and will vest in equal monthly installments through March 23, 2029, conditioned on continued service. Following this award, Julianne holds options for 37,313 underlying shares directly.